| Date | Title | Description |
| 28.08.2026 | Breast Cancer Liquid Biopsy Market Trends: Precision Oncology and Minimally Invasive Diagnostics Driving Growth | The breast cancer liquid biopsy market is emerging as a promising segment of precision oncology as healthcare providers increasingly seek minimally invasive approaches for cancer detection, monitoring, and treatment planning. Liquid biopsy ... |
| 28.07.2026 | Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. | Myriad Genetics processes an estimated 1.5 million diagnostic tests annually, including screening for hereditary cancer and prenatal conditions, tumor profiling, and assessments of how genes may affect the body's response to mental health m... |
| 27.07.2026 | Nano Dimension’s $890 Million AI Healthcare Pivot Now Hangs in the Balance | Last month, Israeli 3D printer manufacturer Nano Dimension signed a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, in a proposed deal valued at $890 million. If completed,... |
| 18.07.2026 | Abbott investigates two separate cyber incidents, says no operations affected | July 17 : Abbott Laboratories is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Friday, adding that its operations w... |
| 20.04.2026 | Digital Health Funding Hits $7.4B in Q1 2026 Driven by AI Drug Discovery and M&A | What You Should Know
The Spending Boom: Healthcare now captures nearly half of all vertical AI spend, projected to hit $1.5 billion in 2025 (more than tripling from $450 million the year prior), according to the latest CB Insights State of ... |
| 30.03.2026 | We’re exiting this tech stock to replenish our cash pile after our annual charity donation | - |
| 05.03.2026 | KeyCare Powers Up AI-Driven Virtual Care with $27.4M Funding | KeyCare secured $27.4 million. Total funding now surpasses $55 million. This Epic-native virtual care company focuses on AI advancement. It plans an AI-powered virtual workforce. This expansion bolsters health system capacity. It dramatical... |
| 03.03.2026 | KeyCare Raises $27.4M in Funding | KeyCare, a Chicago, IL-based Epic-based virtual care company, raised $27.4M in funding.
The round was led by HealthX Ventures with participation from 8VC, LRVHealth, BOLD Capital Partners, and Ikigai Venture Partners, WellSpan Health, Allin... |
| 03.03.2026 | KeyCare: $27.4 Million Raised For Epic-Based Virtual Care Platform Scaling AI-Enabled Primary And Urgent Care | KeyCare, a virtual care company built natively on Epic, announced it has raised $27.4 million in a new financing round to accelerate the expansion of its AI-powered, Epic-based virtual care platform for health systems. The round was led by ... |
| 03.02.2026 | Forward BIOLABS announces first ICP awardees | Forward BIOLABS has announced the first round of awardees for its Innovation to Commercialization Pipeline (ICP) program, a new initiative designed to help early-stage biohealth companies across Wisconsin move closer to market readiness.
Th... |
| 18.12.2025 | Bringing rapid, lab-grade diagnostics to the pond side | - |
| 21.11.2025 | Американская Abbott покупает производителя тестов на рак Exact Sciences за $23 млрд | Американская компания Abbott (ABT.N), базирующаяся в Иллинойсе, планирует приобрести американского производителя тестов на рак Exact Sciences (EXAS.O), штаб-квартира которого находится в Милуоки, в сделке общей стоимостью до $23 млрд с учёт... |
| 12.11.2025 | Laboratory Economics Issues Research Report on U.S. Anatomic Pathology Market | Laboratory Economics has just published the most comprehensive and detailed market research report available on the U.S. Anatomic Pathology Market. This is an ideal resource for preparing business plans and market strategies.
POUGHKEEPSIE, ... |
| 27.10.2025 | Burrell Communications Receives ARF's Highest Honor: Named Grand Winner of the David Ogilvy Awards | The "You Can't Stop My Drive" campaign received the Gold Award in the Cultural Fluency category, for best demonstrating how insights and research can elevate creative work and deliver measurable brand impact. This prestigious awar... |
| 14.09.2025 | Venture Investors Health Fund: $80 Million Closing Of Seventh Fund | Venture Investors Health Fund, one of the Midwest’s longest-standing healthcare-focused venture capital firms, has closed its seventh fund with $80 million in committed capital. The new fund will be used to invest in early-stage healthcare ... |
| 11.07.2025 | Rittenhouse Ventures: Over $75 Million In AUM Following Fund III Closing | Rittenhouse Ventures, a firm with over 15 years of experience backing the country’s top early-stage software founders, announced the closing of Fund III. This new fund will build on the firm’s strong track record of investing in capital-eff... |
| 15.03.2025 | HerHealth Oncology Congress 2025: A Landmark Event in Advancing Women's Cancer Care | The HerHealth Oncology Congress 2025, held on March 1-2, 2025, at the Renaissance Orlando Resort & Spa, brought together leading oncologists, researchers, and healthcare professionals to discuss advancements in women's oncology. Organiz... |
| 18.02.2025 | Swim Across America Welcomes Two New Board Members: Harry Wilcox and Tim Buttigieg | Wilcox and Buttigieg Bring Biotech, Science, Financial, Hospitality and Real Estate Expertise to Help Grow Swim Across America's Impact and Mission
CHARLOTTE, N.C., Feb. 18, 2025 /PRNewswire-PRWeb/ -- Swim Across America, a national nonprof... |
| 27.01.2025 | Five9 Announces its New Era of CX Awards Winners | Five9 (Nasdaq: FIVN), provider of the Intelligent CX Platform, today announced the winners of the New Era of CX Awards 2024. These awards celebrate the most innovative companies and individuals redefining customer experience and AI in busin... |
| 13.01.2025 | Kardigan: $300 Million Raised For Modernizing Cardiovascular Drug Development | Kardigan – a heart health company modernizing cardiovascular drug development – announced it launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they ... |
| 08.01.2025 | Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test | Chris Parker appointed CEO and Board Member
Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President
ST. LOUIS–(BUSINESS WIRE)–January 8, 2025–
Cofactor Genomics, Inc., a commercial-stage... |
| 27.09.2024 | Box Hubs and Iterable's Expansion: A New Era of Collaboration and Innovation | In the fast-paced world of technology, companies are constantly seeking ways to innovate and enhance collaboration. Two recent announcements from Box, Inc. and Iterable highlight this trend. Box has launched Box Hubs, a tool designed to str... |
| 26.09.2024 | Box Announces General Availability of Box Hubs | Box, Inc., the leading Intelligent Content Cloud, announced the general availability of Box Hubs. Box Hubs are simple, customizable portals that revolutionize how individuals and teams curate and publish content across their enterprise. Wit... |
| 18.07.2024 | Frost & Sullivan Institute Celebrates Leaders in Sustainability with 2024 Enlightened Growth Leadership Awards | SANTA CLARA, Calif., July 18, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas (LATAM and North Americas). This... |
| 15.05.2024 | Foundation Fighting Blindness Partners with PreventionGenetics and InformedDNA to Advance My Retina Tracker® Genetic Testing Program | Empowering Healthcare Providers and Patients with Genetic Testing and Genetic Counseling Solutions
COLUMBIA, Md., May 15, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and ... |
| 07.03.2024 | United in the Fight Against Colorectal Cancer | - |
| 07.12.2023 | Exact Sciences, Inc. Exact Sciences presents results from multiple studies supporting optimization and individualization of treatment for breast cancer patients at San Antonio Breast Cancer Symposium(... | Exact Science Co., Ltd.
Exact Sciences Presents Results from Multiple Trials to Help Optimize and Personalize Treatment for Breast Cancer Patients at San Antonio Breast Cancer Symposium®
……
This document is a partial translation of a press ... |
| 07.12.2023 | Exact Sciences, Inc. Exact Sciences presents results from multiple studies supporting optimization and individualization of treatment for breast cancer patients at San Antonio Breast Cancer Symposium(... | - |
| 04.12.2023 | Exact Science Co., Ltd. Exact Science Co., Ltd. launches “Breast Cancer Treatment.jp” website for breast c ancer patients | - |
| 04.12.2023 | Exact Science Co., Ltd. Exact Science Co., Ltd. launches “Breast Cancer Treatment.jp” website for breast c ancer patients | Exact Science Co., Ltd.
Exact Science Co., Ltd. launches “Breast Cancer Treatment.jp” website for breast cancer patients
……
Exact Science Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo,
Representative Director: Kazuhiro Matsumura) will launch B... |
| 17.10.2023 | エグザクトサイエンス株式会社、代表取締役に松村一弘が就任 | 松村は、1986年に日製産業株式会社（現：株式会社日立ハイテク）にてキャリアをスタートし、ライフサイエンス事業の営業（国内、海外）、マーケティング、事業戦略、米国子会社社長などのポジションを歴任してきました。
エグザクトサイエンスの代表取締役はこれまでインターナショナル市場におけるセールス＆マーケティングの副社長であるアントニオ・ラ・レジナが暫定的に兼務しておりました。
この度の新代表取締役の就任により、エグザクトサイエンスは、より一層、患者さんの遺伝子情報に基づいた最先... |
| 12.04.2023 | Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting | Research from Exact Sciences' multi-cancer early detection (MCED) program supports advanced imaging as an optimal and potentially more efficient strategy for identifying cancerous tumor location following a positive MCED test result1
Exact ... |
| 01.02.2023 | Exact Sciences schedules fourth quarter 2022 earnings call | MADISON, Wis., Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. EXAS, a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close ... |
| 08.01.2023 | Exact Sciences Announces Preliminary Fourth Quarter 2022 Results | Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $401.8-$402.8 million and Precision Oncology revenue of $... |
| 16.12.2022 | A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes. | A standard blood draw. Hollis Johnson/Business Insider
Guardant Health said that its blood test to screen for cancer caught 83% of colorectal cancer cases.
Guardant says this could unlock an $20 billion market for colorectal cancer screenin... |
| 18.10.2022 | Viome Life Sciences snags $67M to expand DTC pipeline of at-home tests and wellness products | Biotechnology company Viome Life Sciences will be expanding its development of direct-to-consumer diagnostic tests and wellness products after receiving $67 million in series C funding, the startup announced Tuesday.
Bellevue, Washington-ba... |
| 14.10.2022 | Wisconsin-Japan Biohealth Summit showcases international collaboration | Guest post contributed by BioForward
Across the globe, life science technology advancements are accelerating to promote better health.
The recent Wisconsin-Japan Biohealth Summit, designed to raise awareness of current collaborations while ... |
| 12.05.2022 | Exact Sciences acquires OmicEra Diagnostics | The Planegg-based diagnostics startup OmicEra specializes in large-scale protein analyses. Now it has been acquired for $15 million by Exact Sciences, a U.S. cancer diagnostics company.
Founded in 2019 by a team of leading proteomics scien... |
| 02.05.2022 | Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score[®] Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients | Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score[®] Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Mon, May 02, 2022 07:30 CET Report this content
Oncotype... |
| 21.03.2022 | What makes a biotech a biotech? | The prototypical biotech company is easy to envision: think Moderna, Alnylam, and Genentech.
But what about Pfizer, which claims “biotechnology is [the company’s] foundation?” What about Twist Bioscience, which doesn’t make therapeutics but... |
| 03.01.2022 | Exact Sciences : Supporting Afghan Refugee Efforts | Supporting Afghan Refugee Efforts
In late summer 2021, an urgent humanitarian need arose during the United States military's withdrawal from Afghanistan. Tens of thousands of Afghans were evacuated to locations throughout the U.S. One of th... |
| 23.12.2021 | Exact Sciences : Receives 2021 Climate Champion Awards | For the second year in a row, the Dane County Office of Energy and Climate Change is recognizing Exact Sciences for efforts taken to reduce the company's impact on the environment in its hometown of Madison, Wisconsin.
"Exact Sciences ... |
| 09.12.2021 | Exact Sciences : Commits $500,000 to Urban League Black Business Hub | Exact Sciences Commits $500,000 to Urban League Black Business Hub
By Exact Sciences / December 09, 2021
Company to be a foundational tenant in new facility
MADISON, Wis. - Dec. 9, 2021 - Exact Sciences today announced the company is commit... |
| 08.12.2021 | New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making | MADISON, Wis., Dec. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the cl... |
| 03.12.2021 | Exact Sciences : Going the Extra Mile | Going the Extra Mile
This year, our team turned out on foot and on bike at races across the United States (and beyond) to support cancer survivors and raise awareness. Along the way, many shared the personal "why" that inspires th... |
| 02.12.2021 | Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test | - RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
- Results have already led to updated NCCN Guidel... |
| 23.11.2021 | New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients | MADISON, Wis., Nov. 23, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical ... |
| 27.10.2021 | New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening | New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening
By Exact Sciences / October 26, 2021
MADISON, Wis.- October 25, 2021 - Exact Sciences Corp. (NASDAQ: EX... |
| 11.10.2021 | Exact Sciences : Hosts Maydm Interns | Exact Sciences Hosts Maydm Interns
This summer, Exact Sciences worked with Maydm, a community partner,to host four interns interested in science, technology, engineering and math (STEM) fields. The internship program organized by Maydm give... |
| 16.08.2021 | Exact Sciences : receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan | MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence Score® Program. The test helps guide c... |
| 16.08.2021 | Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan | |
| 28.07.2021 | Exact Sciences Announces Second Quarter 2021 Results | |
| 19.05.2021 | EXACT SCIENCES CORPORATION
Exact Sciences : Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45 | Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
By Exact Sciences / May 19, 2021
National Task Force supports Cologuard® as a screening option and screening expands to a... |
| 18.05.2021 | Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45 | |
| 04.05.2021 | Exact Sciences Announces First Quarter 2021 Results | |
| 28.04.2021 | Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People | |
| 16.02.2021 | Exact Sciences Announces Fourth Quarter 2020 Results | |
| 12.01.2021 | New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard® | |
| 10.01.2021 | Exact Sciences Announces Preliminary Fourth Quarter 2020 Results | |
| 07.10.2020 | Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement | |
| 24.07.2019 | Freenome nabs $160M to advance blood-based colorectal cancer test | Other new investors in the round include Roche Venture Fund, Kaiser Permanente Ventures and the social impact investing arm of the American Cancer Society. The company has raised a total of $238 million since its founding in 2014.
Alongside... |
| 16.04.2019 | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Based on interviews with oncologists, Cannacord analyst Mark Massaro wrote in a note to clients Tuesday that the doctors indicated the NILE study “may usher in a blood-first paradigm” in testing, particularly given the ability to find more ... |
| 19.01.2018 | Exact, Spectrum, PerBlue, & More: This Week’s Wisconsin Watchlist | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
It was a newsy week for Wisconsin’s innovation community. Catch up on some of the major happenings with these recent headlines:
—Exact Sciences’ (NASDAQ: EXAS) stock price fin... |
| 07.02.2017 | Exact Sciences, OnKöl, Fiserv, & More: This Week’s WI Watchlist | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Get caught up to speed on news from Wisconsin’s innovation community with these recent headlines:
—Madison-based Exact Sciences (NASDAQ: EXAS) said that Cologuard, the company... |
| 16.12.2016 | Exact Sciences, Fiserv, OneEvent, & More: This Week’s WI Watchlist | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Stay out of the snow, and in the know, with these recent headlines from Wisconsin’s innovation community.
—Madison-based Exact Sciences (NASDAQ: EXAS) said that Cologuard, the... |
| 06.05.2016 | Fund of Funds, ConsortiEX & Froedtert: This Week’s Wisconsin Roundup | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Wrap up your week with these headlines from Wisconsin’s innovation community:
—The first recipient fund to launch under the Badger Fund of Funds will be The Idea Fund, based i... |
| 05.08.2015 | Report: Big medtech’s ranks are swelling thanks to M&A | “It could be that the economic upturn — at least in the U.S. — is making medtech companies more confident of growing sales and they are hiring accordingly,” the report says.
This is fantastic news for the big players, as the smaller-sized m... |
| 07.04.2014 | Wisconsin Roundup: Startup Weekend, Exact Sciences, 3D Printing | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Last week was a busy one for Wisconsin’s tech and innovation community. Here are a few notable items you might have missed:
—Madison, WI, held its third annual Startup Weekend... |
| 07.01.2010 | Molecular diagnostics company Predictive Biosciences buys OncoDiagnostic Laboratory in Cleveland | Founded in 1985 by Dr. Cirilo F. Galang and other pathologists, OncoDiagnostic Laboratory (ODL) has developed a subspecialty for providing cancer pathology services to hundreds of urology practices nationwide. Galang, who also is president ... |
| - | Freenome nabs $160M to advance blood-based colorectal cancer test | Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer.
In the latest mega funding round, South San Francisco company Freenome ha... |
| - | Report: Big medtech’s ranks are swelling thanks to M&A | Last year was the year of medtech mergers – made patently obvious by a new report from EP Vantage, which tracks job in the sector.
With that Covidien merger, Medtronic has swelled its employee base to more than 90,000 on the payroll worldwi... |
| - | Manage your consent preferences
Madison cancer startup founded by former Exact Sciences exec raises $42M | - |
| - | Viome Life Sciences launches at-home oral/throat cancer test for consumers | Viome Life Sciences, a biotechnology company founded in 2016, has launched CancerDetect, a diagnostic test for oral and throat cancer that uses mRNA technology and an AI-powered platform, the company announced last week.
The test is a direc... |
| - | Molecular diagnostics company Predictive Biosciences buys OncoDiagnostic Laboratory in Cleveland | CLEVELAND, Ohio — Predictive Biosciences Inc., the Lexington, Mass., company that is commercializing biomarker and other non-invasive diagnostics for cancer management, has acquired OncoDiagnostic Laboratory Inc. in Cleveland for undisclose... |
| - | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Published results of a liquid biopsy study in lung cancer patients could lead oncologists to prioritize blood-based genomic sequencing over traditional tissue testing.
Redwood City, California-based Guardant Health said Monday that it had p... |
